Gemifioxacin

Gemifioxacin 구조식 이미지
카스 번호:
175463-14-6
상품명:
Gemifioxacin
동의어(영문):
GEMIFLOXACIN;gemifioxacin;Gemifloxactin;LB-20304 Mesilat;SB-265805 Mesilate;Gemifloxacin Mesilate;Gemifioxacin USP/EP/BP;Canine Gemifloxacin Precursor;DPP-4 Inhibitor Precursor (Pediatric);DPP-4 Inhibitor Precursor (High Selectivity)
CBNumber:
CB3855593
분자식:
C18H20FN5O4
포뮬러 무게:
389.38
MOL 파일:
175463-14-6.mol

Gemifioxacin 속성

녹는점
235-237°
끓는 점
638.9±65.0 °C(Predicted)
밀도
1+-.0.1 g/cm3(Predicted)
산도 계수 (pKa)
6.02±0.70(Predicted)
InChI
InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
InChIKey
ZRCVYEYHRGVLOC-HYARGMPZSA-N
SMILES
N1(C2CC2)C2C(=CC(F)=C(N3C/C(=N\OC)/C(CN)C3)N=2)C(=O)C(C(O)=O)=C1
CAS 데이터베이스
175463-14-6
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
유해 물질 데이터 175463-14-6(Hazardous Substances Data)
그림문자(GHS): Exclamation Mark (GHS07)
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 P264, P270, P301+P312, P330, P501
H315 피부에 자극을 일으킴 피부부식성 또는 자극성물질 구분 2 경고 P264, P280, P302+P352, P321,P332+P313, P362
H319 눈에 심한 자극을 일으킴 심한 눈 손상 또는 자극성 물질 구분 2A 경고 P264, P280, P305+P351+P338,P337+P313P
H335 호흡 자극성을 일으킬 수 있음 특정 표적장기 독성 - 1회 노출;호흡기계 자극 구분 3 경고
예방조치문구:
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P305+P351+P338 눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

Gemifioxacin C화학적 특성, 용도, 생산

개요

LG Life Sciences (formerly LG Chemical) has developed gemifloxacin (SB-265805, LB-20304a), a fluoronaphthyridone active against both Gram-positive and Gram-negative bacteria, including methicillin-resistant staphylococci, as a treatment for bacterial infection. By December 2002, the drug had been approved in Korea.

정의

ChEBI: A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.

Antimicrobial activity

The broad antibacterial spectrum embraces most Gram-positive cocci (including high potency against Str. pneumoniae) and Gram-negative bacilli. It possesses a high affinity for pneumococcal topoisomerase IV. Activity against Gram-negative respiratory tract pathogens such as H. influenzae, Mor. catarrhalis, Ch. pneumoniae, L. pneumophila and Mycoplasma pneumonia is good. It is relatively inactive against Ps. aeruginosa and Enterococcus spp. Activity against Enterobacteriaceae is similar to that of moxifloxacin but it is less potent against anaerobes. Gemifloxacin is inactive against M. tuberculosis. Activity against Nocardia asteroides (MIC 0.5–1 mg/L) is better than that of other quinolones other than the investigational compound nemonoxacin .
Multistep resistance studies suggest that it is less likely than other quinolones to select for quinolone-resistant Str. pneumoniae strains. Because it inhibits both DNA gyrase and DNA topoisomerase IV enzyme systems at therapeutically relevant drug levels in Str. pneumoniae, single mutations in parC or gyrA result in only a small increase in the MIC. In Str. pneumoniae gyrA mutations arise at a lower rate (1.6 × 1011) than mutations in parC. It seems to be unaffected clinically by quinolone efflux mechanisms in Str. pneumoniae. Low rates of resistance selection have also been reported in H. influenzae.

Pharmaceutical Applications

A fluoronaphthyridone derivative with a dual substituted pyrrolidine moiety at the C-7 position. It is formulated as the mesylate.

Pharmacokinetics

absorption and distribution
In oral escalating dose studies (single doses of 20–800 mg), Cmax ranged from 0.12 to 4.33 mg/L after an average of 1 h. Antacids significantly reduce the systemic availability and protein binding is relatively high. Excellent concentrations are achieved in serum as well as various tissues such as bronchial mucosa, epithelial lining fluid and alveolar macrophages. Absolute bioavailability of the 320 mg oral tablet is around 71%. Pharmacokinetics are not significantly altered when administered with a high fat meal.
Metabolism and excretion
The apparent elimination half-life ranges from 6 to 9 h, and 26–40% of administered doses are eliminated in urine. It is metabolized to a limited extent in the liver. Cytochrome P450 enzymes do not play an important role in metabolism, and the metabolic activity of these enzymes is unaffected. Around 65% of the parent compound and its metabolites are eliminated in the feces and the remainder in the urine. The mean renal clearance after repeated doses of 320 mg is about 11.6 L/h, indicating active renal secretion. The mean apparent elimination half-life at steady state following administration of 320 mg to healthy subjects was approximately 7 h. No dosage adjustment is recommended in patients with mild, moderate or severe hepatic impairment. Clearance is reduced and plasma elimination is prolonged in patients with renal insufficiency, leading to an average increase in AUC values of c. 70%. Hemodialysis removes approximately 20–30% of an oral dose from plasma.

Clinical Use

Community-acquired pneumonia in adults
Acute exacerbations of chronic bronchitis in adults

부작용

The most commonly reported side effects are diarrhea (3.6%), rash (2.8%) and nausea (2.7%). No evidence has emerged of a clinically significant prolongation in QTc interval. The phototoxicity potential is low and similar to that seen with ciprofloxacin. The overall incidence of drugrelated rash is 2.8%. The rash is most commonly mild, macropapular (occasionally urticarial), predominantly selflimiting, and mainly occurs in women under 40 years and in postmenopausal women on hormone replacement therapy after ≥10 days.

Gemifioxacin 준비 용품 및 원자재

원자재

준비 용품


Gemifioxacin 공급 업체

글로벌( 92)공급 업체
공급자 전화 이메일 국가 제품 수 이점
shilang(zhuoli group)-pharma(nanjing) co.,ltd. 86-25-87797880,81,82 -809
shilang@shilang-pharma.com China 40 55
JinYan Chemicals(ShangHai) Co.,Ltd. 13817811078
sales@jingyan-chemical.com China 9963 60
LGM Pharma 1-(800)-881-8210
inquiries@lgmpharma.com United States 2110 70
China Langchem Inc. 0086-21-58956006
China 7798 57
Chengdu Green Young Biomedical Technology Co., Ltd. 86+28-85337952 18081025021
greenyoung@glykj.com China 93 62
Beijing HuaMeiHuLiBiological Chemical 010-56205725
waley188@sohu.com China 12323 58
Chizhou Kailong Import and Export Trade Co., Ltd.
xg01_gj@163.com China 9413 50
AN PharmaTech Co Ltd 86(21)68097365
sales@anpharma.net China 4874 55
Shanghai Synchem Pharma Co., ltd 21-619849051-1 18521059765
synchempharma@aliyun.com China 4987 55
Pharmacodia (Beijing) Co.,Ltd +86-400-851-9921
sales@pharmacodia.com China 2307 55

Gemifioxacin 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved